European Biotech: The Flowering of an Industry or Tulip II?
This article was originally published in Start Up
The central message at the Atlas Venture/Ernst & Young European Life Science Conference: the European start-up scene is red hot--hotter than it is in the US. One key reason for a flood of start-ups is the flood of venture funding which has followed the extraordinary performance (until recently) of UK biotech stocks. Another impetus has been Jurgen Ruttgers, Germany's minister of education and research, who has encouraged start-ups through various government spending programs.
You may also be interested in...
As Germany's insurers try out new drug reimbursement tactics, innovative pharmas have responded with novel, brand-boosting payor deals of their own. A report from the leading edge of European marketing strategies.
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.